C-peptide ELP Biopolymer for Diabetic Complication Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional treatments for diabetic complications, such as diabetic angiopathy, are limited by the short half-life of C-peptide when injected, requiring frequent administration and high production costs, and can induce immune responses due to long-term circulation of PEG molecules.
Innovation Solution
A pharmaceutical composition comprising C-peptide bound to a temperature-sensitive biopolymer, specifically elastin-like polypeptide (ELP), which allows for continuous release of C-peptide in vivo through a single injection, reducing production costs and minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If C-peptide is injected to treat diabetic complications, then therapeutic effect is achieved, but half-life is short requiring frequent administration
Solution Approach 1:
The patent uses a temperature-sensitive biopolymer (elastin-like polypeptide) as an intermediary carrier to bind C-peptide. This mediator enables controlled release of C-peptide at the target site, extending its effective duration and reducing the need for frequent injections while maintaining therapeutic efficacy.
Solution Approach 2:
The patent utilizes temperature-sensitive phase transition of the elastin-like polypeptide to control C-peptide release. By changing temperature parameters, the system transitions between sol and gel states, enabling controlled release kinetics that extend the half-life of C-peptide and reduce administration frequency.
2Duration of action of moving object
If PEG is used to extend C-peptide circulation, then half-life is improved, but immune response is induced
Solution Approach 1:
The patent replaces long-circulating PEG molecules with a biodegradable temperature-sensitive biopolymer that can be metabolized by the body. This disposable-like approach allows the carrier to fulfill its drug delivery function and then be naturally eliminated, avoiding the immune responses associated with persistent foreign molecules like PEG.
Solution Approach 2:
The patent creates a composite system combining C-peptide with elastin-like polypeptide, forming a new material with properties superior to either component alone. This composite approach achieves extended circulation without the immunogenicity of PEG, as the biopolymer is composed of natural amino acid sequences that are more biocompatible.
3Ease of manufacture
If chemical synthesis is used to produce C-peptide, then production is achieved, but cost is high
Solution Approach 1:
The patent replaces chemical synthesis methods with biological production using recombinant DNA technology. By substituting chemical processes with biological expression systems, the manufacturing process becomes more scalable and cost-effective, leveraging cellular machinery to produce the peptide sequence.
Solution Approach 2:
The elastin-like polypeptide sequence can be produced through standardized recombinant expression protocols that are universally applicable. This multi-functional approach allows the same production platform to generate both the carrier protein and the therapeutic C-peptide, reducing overall manufacturing complexity and cost.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The C-peptide bound to ELP effectively inhibits apoptosis, ROS levels, and transglutaminase 2 activity, providing long-term therapeutic effects for diabetic complications like retinopathy, nephropathy, and cardiovascular disease without the need for frequent injections or high production costs.
Implementation Method 1
C-peptide bound to a temperature-sensitive biopolymer (elastin-like polypeptide)... C-peptide bound to ELP... phase-transition behavior
Data Source
AI summary
Disclosed is a composition and a method for the prevention or treatment of diabetic complications, which includes C-peptide bound to elastin-like polypeptide (ELP) and is thus capable of effectively preventing or treating diseases resulting from hyperglycemia, which is a major cause of diabetes, for example, diabetic retinopathy, and the like.